Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Maureen Riordan

Senior Deals Analyst

Connecticut, US
Maureen has been with Strategic Transactions for 20 years, first as a Research Analyst, now as a Senior Deals Analyst, with a brief in-between stint as Editor/Contributor for Start-Up company profiles. In her current role, she primarily researches, analyzes, writes, and edits summaries involving current biopharma and medtech deals – which appear in the ST database and the monthly dealmaking section of In Vivo – and also writes and updates legacy deals. Maureen regularly co-authors a quarterly statistics column covering deal trends in both the biopharma and medtech industries for In Vivo. Prior to joining Strategic Transactions, Maureen was a corporate librarian in a management consulting firm fielding search requests for in-house analysts, and then spent two years with Lexis-Nexis as a customer consultant having daily contact with client subscribers to teach database searching techniques. Maureen holds a Bachelor of Arts degree in English from Niagara University, and a Master of Library Science degree from Southern Connecticut State University.

Latest From Maureen Riordan

Deals in Depth: January 2024

Ten $1bn+ alliances were penned in January. In the top alliance by deal value, Shanghai Argo Biopharmaceutical entered into exclusive collaboration with Novartis Pharma for two undisclosed Argo cardiovascular disease programs, one in Phase I and another in Phase I/IIa. Novartis gets an exclusive global license to develop and commercialize the Phase I program and also receives an option to potentially license compounds directed against up to two additional targets. For the Phase I/IIa program, Novartis gets an exclusive license worldwide except in Greater China. The deal could be worth up to $4.17bn for Argo.

Deals Market Intelligence

Dealmaking Quarterly Statistics, Q4 2023

During Q4, biopharma merger and acquisition deal value reached $63bn and drew in $75.4bn in potential deal value from alliances. Device company M&A values reached $4.8bn, while in vitro diagnostics and research tools players’ M&A activity totaled $3.4bn.

BioPharmaceutical Medical Device

Financing Quarterly Statistics, Q4 2023

During the fourth quarter, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $1.1bn; while in vitro diagnostic firms and research tools players raised $459m.

Deals Financing

Deals in Depth: December 2023

Six $1bn+ alliances were penned in December. In the top alliance by deal value, Biokin and its SystImmune subsidiary licensed Bristol Myers Squibb exclusive rights to develop and commercialize its cancer candidate BL-B01D1 worldwide, excluding Mainland China where SystImmune retains rights. BMS will pay $800m up front, up to $500m in contingent near-term payments, and up to $7.1bn in development, regulatory, and sales milestones, for a total potential consideration of up to $8.4bn.

Deals Financing

Deals in Depth: November 2023

Five $1bn+ alliances were penned in November. In the top alliance by deal value, Cellectis and AstraZeneca entered into a joint research collaboration agreement to accelerate the development of next-generation therapeutics in areas of oncology, immunology and rare diseases. The deal could be worth up to $2.4bn. AstraZeneca will leverage Cellectis’ proprietary gene editing technologies and manufacturing capabilities to design novel cell and gene therapy candidate products. A total of 25 genetic targets have been exclusively reserved for AstraZeneca, which holds an option to license exclusive global rights to develop and sell up to 10 of the targets, to be exercised before IND filing.

Deals Financing

Deals In Depth: October 2023

Nine $1bn+ alliances were penned in October. Topping the list was a potential $22bn deal between Daiichi Sankyo and Merck for the global development and commercialization of Daiichi’s DXd antibody drug conjugate candidates patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan.  

Deals Financing
See All